TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28476931
Drug: Genetic variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic variant rs11014566 (G allele)
Study: 28477061
Drug: Telaprevir in
Normalized name: Product containing telaprevir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir in combination with peg-interferon and ribavirin (Peg-IFN/RBV)
Study: 28478485
Drug: Radium-223 dichloride
Normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radium-223 dichloride (55 kBq/kg body weight every 4 weeks for up to six injections)
Study: 28478485
Drug: Radium-223 dichloride
Normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radium-223 dichloride (initial single injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W)
Study: 28478485
Drug: Radium-223 dichloride
Normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radium-223 dichloride (overall treatment)
Study: 28480334
Drug: 4-valent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-valent HPV (4vHPV) vaccine
Study: 28482144
Drug: Canakinumab 300
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 300 mg subcutaneously every 6 weeks during period 1 (P1)
Study: 28482144
Drug: Canakinumab treatment
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab treatment during period 1 (P1)
Study: 28482144
Drug: Canakinumab treatment
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab treatment during period 2 (P2)
Study: 28482146
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue (SAT) measurement
Study: 28482908
Drug: Adenovirus-specific T
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus-specific T cell (ADV-VST) infusion from HSCT donor or third party haploidentical donor
Study: 28482908
Drug: Adenovirus-specific T
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus-specific T cell (ADV-VST) infusion
Study: 28483716
Drug: Prophylactic donor
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease (MRD) test and graft-versus-host disease (GVHD)-guided multiple DLIs.
Study: 28483828
Drug: Salt added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt added in home food preparation
Study: 28483828
Drug: Home tap
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home tap water consumed as a beverage and dietary supplement and nonprescription antacids
Study: 28483965
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) at a dose of 25 mg/kg of body weight/day
Study: 28484421
Drug: PCTus-based antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCTus-based antibiotic therapy guidance in addition to stroke unit care
Study: 28484650
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgical treatment (keyhole approach)
Study: 28484650
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard surgical treatment (not specified)
Study: 28484958
Drug: Diuretic resistance
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic resistance defined by fractional sodium excretion (FeNa) <0.2%
Study: 28484958
Drug: Diuretic resistance
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic resistance defined by urinary sodium <50 meq/L
Study: 28484958
Drug: Diuretic resistance
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic resistance defined by urinary Na/K ratio <1.0
Study: 28484958
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of definitions of diuretic resistance
Study: 28485816
Drug: Classic systemic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic systemic therapies
Study: 28487034
Drug: Multiple biomarker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple biomarker score including NT-proBNP, kidney injury molecule-1, osteopontin, and tissue inhibitor of metalloproteinase-1
Study: 28487491
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally daily on days 1-21 of a 28-day cycle
Study: 29095678
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for up to 24 months
Study: 28489732
Drug: NVP prophylactic
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP prophylactic dosing (WHO weight-band recommendations)
Study: 28489732
Drug: NVP therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP therapeutic dosing (6 mg/kg twice daily)
Study: 28494506
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (HMA) including decitabine (DAC) and azacitidine (AZA) after induction/consolidation with fludarabine, cytarabine, and G-CSF (FLAG) with low dose gemtuzumab or idarubicin.
Study: 28494798
Drug: chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chronic low-dose step up protocol with recombinant human FSH (rhFSH)
Study: 28495029
Drug: Delafloxacin 450
Normalized name: delafloxacin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 450 mg every 12 hours from days 3 to 8
Study: 28495029
Drug: Midazolam 5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 5 mg oral dose on days 1 and 8
Study: 28495639
Drug: CPI-613 in
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m², leucovorin, irinotecan, and fluorouracil)
Study: 28495794
Drug: Complete or
Normalized name: Canker Complete Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment
Study: 28497258
Drug: Veliparib administered
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib administered orally at doses ranging from 10 to 80 mg twice daily on days 1-7
Study: 28497258
Drug: Temozolomide administered
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide administered orally at 150-200 mg/m2
Study: 28497757
Drug: Veliparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (400 mg twice daily) combined with capecitabine (825 mg/m2) and radiotherapy
Study: 28498618
Drug: CDCA1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA1 peptide vaccination (1.0 mg)
Study: 28498618
Drug: CDCA1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA1 peptide vaccination (3.0 mg)
Study: 28498880
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy (30 mg/m2 docetaxel, 40 mg/m2 cisplatin, 2000 mg/m2 fluorouracil per week)
Study: 28499389
Drug: Tumor resection
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor resection and combined radio-chemotherapy
Study: 28501811
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with advanced virtual stenting technique and porous media method for haemodynamic simulations.
Study: 28501909
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist therapy (VKA)
Study: 28502418
Drug: Budesonide/formoterol (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (fixed-dose strategy)
Study: 28502892
Drug: Adequate initial
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate initial antibiotic therapy
Study: 28503190
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of essential amino acids (EAA)
Study: 28503190
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of essential amino acids (EAA) with chloroquine (CQ)
Study: 28504860
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) expanded in vitro, dose 1-2 × 10^6 cells/kg
Study: 28504996
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 7 mL/kg administered for 30 minutes after opening the thoracic cavity.
Study: 28505327
Drug: SAHA (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAHA (5-day intraperitoneal administration)
Study: 28506306
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment during the study period
Study: 28506390
Drug: OM3-CA 4
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA 4 g once daily for 13 days with rosuvastatin 40 mg (single dose) co-administered with the 11th dose.
Study: 28506390
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg plus acetylsalicylic acid 81 mg daily for 14 days with or without OM3-CA.
Study: 28506516
Drug: 5 doses
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 doses of DTaP vaccine
Study: 28506516
Drug: Any DTaP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any DTaP vaccine
Study: 28507113
Drug: Binuclear Cyclopalladated
Normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binuclear Cyclopalladated Compound Therapy
Study: 28508253
Drug: DEBDOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBDOX treatment
Study: 28508945
Drug: Cryoablation combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation combined with allogenic NK cell immunotherapy
Study: 28510797
Drug: Morphine-3-Glucuronide (M3G)
Normalized name: MENTHOL GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-3-Glucuronide (M3G)
Study: 28510797
Drug: Morphine-6-Glucuronide (M6G)
Normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-Glucuronide (M6G)
Study: 28511673
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg orally once daily until disease progression or intolerable toxicity
Study: 28511692
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg paricalcitol daily
Study: 28511692
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg paricalcitol daily
Study: 28511709
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) after nine cycles of induction chemotherapy.
Study: 28514929
Drug: Image-guided accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT) at 70Gy(RBE) in 28 fractions for low-risk disease
Study: 28514929
Drug: Image-guided accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT) at 72.5Gy(RBE) in 29 fractions for intermediate-risk disease
Study: 28514929
Drug: Image-guided accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT)
Study: 28515269
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation (10 mL·d)
Study: 28522574
Drug: Nilotinib, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib, oral administration, monitored within three hours of administration.
Study: 28522574
Drug: Nilotinib, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib, oral administration, monitored within seven days.
Study: 28523161
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 5,000 U, bid preoperatively upon admission
Study: 28523482
Drug: Physician-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-driven titration of BIAsp 30
Study: 28523582
Drug: Integrin-targeting radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrin-targeting radiopharmaceuticals (200 MBq injection)
Study: 28525370
Drug: Metronomic vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic vinorelbine (60 mg on Day 1, 30 mg on Day 2, and 60 mg on Day 4 weekly until progression)
Study: 28526489
Drug: Intravitreous injection
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous injection of AAV2-sFLT01
Study: 28526542
Drug: Diabetes mellitus
Normalized name: diagnostic,monitoring agents for diabetes mellitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes mellitus treated with oral medication or insulin
Study: 28527133
Drug: TAK-264 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-264 1.8 mg/kg
Study: 28528010
Drug: Sustained-Release Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sustained-Release Bimatoprost Ocular Ring
Study: 28528875
Drug: Central augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central augmentation pressure
Study: 28528917
Drug: Pazopanib 600mg
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o.
Study: 28529313
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride and low-dose IL-2
Study: 28529748
Drug: Local modulated
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local modulated electro-hyperthermia (mEHT) combined with traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, applied for 60 min every second day for 4 weeks (14 sessions); TCM decoction administered orally at 400 ml daily.
Study: 28529748
Drug: Standard intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intraperitoneal chemoinfusion (IPCI) with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2).
Study: 28531175
Drug: High-dose liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose liposomal amphotericin B (L-AmB) 10 mg/kg/week for 2 weeks
Study: 28531305
Drug: IAA (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAA (Insulin Autoantibodies)
Study: 28531455
Drug: Control (Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Cream of Rice)
Study: 28531881
Drug: CAP7.1 (45,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP7.1 (45, 90, 150, and 200 mg/m²)
Study: 28531881
Drug: CAP7.1 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP7.1 (intravenous infusion for 5 consecutive days)
Study: 28533916
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 1 mg/kg once daily until no longer needing mechanical ventilation
Study: 28535181
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg daily combined with paclitaxel 175 mg/m2 and carboplatin AUC 5 every 3 weeks for a maximum of four cycles followed by maintenance everolimus 5 mg daily until progression
Study: 28535298
Drug: Ledipasvir-Sofosbuvir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-Sofosbuvir plus Ribavirin (90 mg and 400 mg) for 12 weeks
Study: 28535817
Drug: Intravenous transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous transplantation of autologous bone marrow mesenchymal stromal cells (BMMSCs)
Study: 28536126
Drug: Highest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest intake of total sugars (median 137 g/d)
Study: 28536126
Drug: Highest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest intake of fructose (median 35.2 g/d)
Study: 28536126
Drug: Highest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest intake of sucrose (median 78 g/d)
Study: 28536126
Drug: Lowest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest intake of total sugars (median 65 g/d)
Study: 28536126
Drug: Lowest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest intake of fructose (median 9.7 g/d)
Study: 28536126
Drug: Lowest intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest intake of sucrose (median 25.8 g/d)
Study: 28537061
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg QD plus lamivudine 300 mg QD
Study: 28538136
Drug: Evinacumab (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab (human monoclonal antibody)
Study: 28538136
Drug: Control antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control antibody
Study: 28539464
Drug: Reparixin in
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin in combination with Weekly Paclitaxel
Study: 28539464
Drug: Weekly Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly Paclitaxel
Study: 28540640
Drug: Abemaciclib, doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib, doses ranging from 50 to 225 mg every 24 hours and 75 to 275 mg every 12 hours
Study: 28542316
Drug: Non-reinstitution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-reinstitution of aspirin until discharge
Study: 28543053
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks
Study: 28546135
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with 5 days of hypofractionated radiotherapy (25 Gy in 5 fractions) during the second cycle of doxorubicin.
Study: 28546135
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with hypofractionated RT.
Study: 28546135
Drug: Hypofractionated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated RT combined with chemotherapy.
Study: 28546463
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day plus Prednisone 5 mg b.i.d.
Study: 28546581
Drug: Panobinostat (PAN)
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat (PAN) 30 mg plus Azacitidine (AZA) 75 mg/m²
Study: 28546581
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) monotherapy
Study: 28549082
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion in patients with frontal brain tumours
Study: 28549424
Drug: Therapist-guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-based cognitive behavior therapy (ePlus) for 12 weeks
Study: 28549424
Drug: Therapist-guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-based cognitive behavior therapy (ePlus)
Study: 28551359
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks)
Study: 28554602
Drug: Buprenorphine medication-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine medication-assisted treatment (B-MAT)
Study: 28555039
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) supplementation, dosage and duration not specified
Study: 28558812
Drug: Onsite antenatal
Normalized name: DRESSING,OPSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onsite antenatal syphilis screening intervention including onsite training, provision of supplies and medicines, quality control and supervision.
Study: 28559537
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT)
Study: 28562108
Drug: Histamine-2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2-receptor antagonists (H2RAs)
Study: 28566263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Treatment as usual with the endocrinologist and the nurse + Bodyguard2)
Study: 28567369
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral agents (DAAs) treatment